For­ma­tion Bio, an AI-fo­cused biotech that ac­quires out­side as­sets, de­vel­ops them and then hands them off, has raised ...

HHS on Wednes­day said it will stop en­forc­ing a ban on the com­pound­ing of cer­tain pop­u­lar pep­tides used for well­ness pur­pos­es while the FDA works on rule­mak­ing to ad­dress the sub­stances ...

Pfizer’s flood-damaged Gujarat cancer drug plant won’t resupply until 2028, deepening US chemotherapy shortages, ASHP said.

Astellas takes an option on Audax’s preclinical IL-12 drug DAX-044 for $285M upfront and option fees, plus up to $1.05B in ...

AstraZeneca delays a third lung cancer readout to 2027 after a run of trial failures, raising pressure on next year’s data.

Zocdoc will let AI agents like Instinct and Google's Gemini book doctor appointments, ensuring verified doctors and insurance coverage.

Scientists are the biggest converts in Endpoints Signal’s Q3 survey, with 78% of them now saying they expect AI to boost drug ...

Plowshare Therapies, led by Kevin Strauss, aims to develop a gene therapy for maple syrup urine disease, targeting ...

Anthropic buys Mithril Medicine, a one-person stealth biotech backed by Atlas whose founder ran the “Professor Oak” account ...

Eli Lilly's Jacob Van Naarden leads aggressive dealmaking to offset tirzepatide's patent cliff, with 12+ acquisitions that ...

BioNTech and DualityBio weigh next steps after HER2 ADC trastuzumab pamirtecan posts a modest Phase 3 win in HER2-low breast ...

Microsoft’s MAI-DxO diagnosed 83% of complex journal cases vs. 36% for doctors; a Beth Israel triage study starts within ...